BioSpace News Archive

Exo (pronounced “echo”), a pioneering health information and medical devices company, today announced that it is acquiring Medo, a Canadian developer of artificial intelligence (AI) technology, to make ultrasound imaging faster and simpler to use.

AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface diseases, announced today that it has launched an enhanced version of its rapid Ocular Immunoglobulin E (IgE) test in response to a study recently published in Nature by researchers at the University of Michigan Department of Climate and Space Sciences and Engineering.

Synaptogenix, Inc. (Nasdaq: SNPX) (“the Company”), today announced changes to its Scientific Advisory Board (SAB) in preparation for Phase 2 data from its Phase 2b clinical trial of Bryostatin-1 for patients suffering from advanced and moderately severe Alzheimer’s disease (AD).

Orphalan SA (“Orphalan” or “the Company”), an international orphan drug development and commercialization company, today announces the enrolment of the first five patients into the International Wilson’s Disease Patient Registry (“iWD Registry”), the first global registry of patients with Wilson’s Disease.

Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces that it has signed a new Licence and Supply Agreement (“LSA”) with an undisclosed US-based private biotechnology company advancing a new generation of adoptive cell therapies.

Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, August 4, 2022 at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2022.

Gritstone bio, Inc. announced that the company’s Board of Directors has granted three employees nonqualified stock options to purchase an aggregate of 29,200 shares of its common stock with an exercise price of $2.68, which is equal to the closing price of Gritstone’s common stock on July 15, 2022, the last trading day preceding the grant date of the awards.

Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced the appointment of Steven E. Hyman, M.D., to its Board of Directors effective July 25.

Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced that the company has enrolled the first patient in a study evaluating the safety and efficacy of the Technolas® TENEO™ excimer laser* for laser-assisted in situ keratomileusis (LASIK) vision correction surgery for hyperopia with astigmatism.

Generate Biomedicines, whose machine learning-powered generative biology platform can rapidly invent new drugs across a wide range of protein modalities and previously undiscoverable protein therapeutics, today announced that Alexandra Snyder, M.D. has been named Chief Medical Officer.